Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2012-09-25

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-0615PMID 23012248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

  2012cited by this paper
• Negative feedback and adaptive resistance to the targeted therapy of cancer.

  2012cited by this paper
• Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.

  2012cited by this paper
• Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011influential reference
• C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

  2011cited by this paper
• Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

  2011cited by this paper
• Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

  2011influential reference
• RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function.

  2011cited by this paper
• Lung cancer: New biological insights and recent therapeutic advances

  2011cited by this paper
• Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

  2011cited by this paper
• Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

  2011cited by this paper
• Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

  2011cited by this paper
• An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

  2011cited by this paper
• Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

  2011cited by this paper
• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  2010cited by this paper
• Global Patterns of Cancer Incidence and Mortality Rates and Trends

  2010cited by this paper
• Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo

  2010cited by this paper
• Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.

  2010cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

  2010cited by this paper
• Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

  2010cited by this paper
• Heat Shock Protein 90 as a Drug Target: Some Like It Hot

  2009cited by this paper
• PIKKing on PKB: regulation of PKB activity by phosphorylation.

  2009cited by this paper
• Ras signaling and therapies.

  2009cited by this paper
• KRAS mutations in non-small cell lung cancer.

  2009influential reference
• The Hsp90 chaperone machinery: from structure to drug development.

  2009cited by this paper
• Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

  2009cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

  2008cited by this paper
• Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.

  2008cited by this paper
• Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

  2008cited by this paper
• Phosphorylation by Akt disables the anti-oncogenic activity of YB-1

  2008cited by this paper
• Heat shock protein 90: The cancer chaperone

  2007cited by this paper
• Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells

  2007cited by this paper
• Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

  2006cited by this paper
• Akt-Mediated YB-1 Phosphorylation Activates Translation of Silent mRNA Species

  2006cited by this paper
• V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

  2006cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004cited by this paper
• The role of nuclear Y-box binding protein 1 as a global marker in drug resistance.

  2004cited by this paper
• Ras Family Signaling: Therapeutic Targeting

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.

  2001cited by this paper

• High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma

  2026cites this paper
• Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

  2025cites this paper
• Targeting KRAS in gynecological malignancies

  2024cites this paper
• Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

  2024cites this paper
• Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice

  2023cites this paper
• Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.

  2022cites this paper
• Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

  2022cites this paper
• Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies

  2022cites this paper
• Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

  2021cites this paper
• mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism.

  2021cites this paper
• Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics

  2021cites this paper
• Introns control stochastic allele expression bias

  2021cites this paper
• KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)

  2020cites this paper
• TIAM1 Upregulation Confers NVP-BEZ235 Resistance to Breast Cancer Cells Through FGFR/STAT3 Pathway

  2020cites this paper
• DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells

  2020cites this paper
• Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib

  2019cites this paper
• Defining and targeting adaptations to oncogenic KRASG12C inhibition using quantitative temporal proteomics

  2019influential citation
• A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

  2019cites this paper
• Chaperone biomarkers of lifespan and penetrance track the dosages of many other proteins

  2019cites this paper
• Targeting Mutant KRAS for Anticancer Therapy.

  2019cites this paper
• Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.

  2019cites this paper
• Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy

  2019cites this paper
• Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma

  2019cites this paper
• Polymeric Micelles in Management of Lung Cancer

  2019cites this paper
• Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors

  2019cites this paper
• hsp-16.2 chaperone biomarkers track physiological states of proteome dosage

  2018cites this paper
• Differences in protein dosage underlie nongenetic differences in traits

  2018cites this paper
• KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

  2018cites this paper
• Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

  2018cites this paper
• CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.

  2018cites this paper
• Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)

  2018cites this paper
• A combined tissue‐engineered/in silico signature tool patient stratification in lung cancer

  2018cites this paper
• KCNQ1OT1 facilitates progression of non‐small‐cell lung carcinoma via modulating miRNA‐27b‐3p/HSP90AA1 axis

  2018cites this paper
• ENHANCING RADIATION SENSITIVITY IN NON-SMALL CELL LUNG CANCER

  2018cites this paper
• HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC

  2018cites this paper
• Novel approach to cancer therapeutics using comparative cancer biology

  2018cites this paper
• Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.

  2017cites this paper
• Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

  2017cites this paper
• Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network

  2017cites this paper
• Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery

  2017cites this paper
• Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

  2017cites this paper
• Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review).

  2017cites this paper
• Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria.

  2017cites this paper
• Oncogene-Driven Metabolic Alterations in Cancer

  2017cites this paper
• Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach

  2017cites this paper
• Reactivation of the p90RSK–CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2–M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC

  2017cites this paper
• Oncogene driver mutations and copy number variation as markers for predicting drug resistance and disease outcome in NSCLC

  2017cites this paper
• KRAS et adénocarcinome bronchique. Entre déceptions et espoirs

  2016cites this paper
• Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.

  2016cites this paper
• Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.

  2016cites this paper
• KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

  2016cites this paper
• Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

  2016cites this paper
• HSP90 inhibitors in lung cancer: promise still unfulfilled.

  2016cites this paper
• Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

  2016cites this paper
• [KRAS and bronchial adenocarcinoma. Between disappointments and hopes].

  2016cites this paper
• The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

  2016cites this paper
• Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation

  2016cites this paper
• Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

  2016cites this paper
• HSP90 as a novel molecular target in non-small-cell lung cancer

  2016cites this paper
• Determining mechanisms of sensitivity and resistance to HSP90 inhibition in non-small cell lung cancer

  2016cites this paper
• Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition

  2015cites this paper
• Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90

  2015cites this paper
• Ganetespib: research and clinical development

  2015cites this paper
• BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

  2015cites this paper
• Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer

  2015cites this paper
• KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.

  2015cites this paper
• New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer

  2015cites this paper
• HSP90 Inhibition Suppresses Lipopolysaccharide-Induced Lung Inflammation In Vivo

  2015cites this paper
• Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

  2015cites this paper
• KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

  2015cites this paper
• Implications of KRAS mutations in acquired resistance to treatment in NSCLC

  2015cites this paper
• Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

  2015cites this paper
• The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells

  2015cites this paper
• Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization

  2015cites this paper
• An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein

  2014cites this paper
• Targeting Ectopic Hsp90 in Breast Cancer

  2014cites this paper
• Cell Death and Survival mTOR Inhibition Potentiates HSP 90 Inhibitor Activity via Cessation of HSP Synthesis

  2014cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.

  2014cites this paper
• Heat shock protein 90 inhibitors in non-small-cell lung cancer

  2014cites this paper
• Inhibition of Breast Cancer Metastasis Suppressor 1 Promotes a Mesenchymal Phenotype in Lung Epithelial Cells That Express Oncogenic K-RasV12 and Loss of p53

  2014cites this paper
• The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

  2014cites this paper
• Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

  2014cites this paper
• The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

  2014cites this paper
• Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models

  2014cites this paper
• Targeting the heat shock protein 90 with the novel small-molecule inhibitor NW457 sensitizes tumor cells to ionizing radiation

  2014influential citation
• Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future

  2014cites this paper
• mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis

  2014cites this paper
• The role of genetic and other biomarkers in NSCLC prognosis

  2014cites this paper
• Influence des caractéristiques morphologiques et mutationnelles des carcinomes pulmonaires sur leur environnement immunitaire et leur pronostic

  2014cites this paper
• Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.

  2014cites this paper
• T ARGETED T HERAPIES IN N ON -S MALL C ELL L UNG C ANCER

  2014cites this paper
• The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting

  2013cites this paper
• mTOR pathway in colorectal cancer: an update

  2013cites this paper
• Adaptive resistance to targeted therapies in cancer.

  2013cites this paper
• Cancer Therapy : Preclinical Preclinical Activity Pro fi le and Therapeutic Ef fi cacy of the HSP 90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

  2013cites this paper
• KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer

  2013cites this paper
• Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

  2013cites this paper
• Personalizing Therapy in Advanced Non–Small Cell Lung Cancer

  2013cites this paper
• KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.

  2013cites this paper